

Stabilization of Live Attenuated Virus Vaccines


Dr. Reinhard Vehring MedImmune Vaccines, Inc. 319 North Bernado Avenue Mountain View, CA 94043

Outline

- Model System
- Stabilization Strategy
- Processing Options
- Results
- Conclusions



Live, Attenuated Influenza Virus Vaccine



Enveloped RNA virus

- Live, cold adapted, attenuated
- Temperature sensitive

< 0.1% w/w of total protein is virus

- Mainly egg derived proteins & metabolites
- Only 1 10 % of virus is infectious

Relatively poorly characterized


- Limited molecular analytical assays
- Limited spatially resolved assays
- Primary formulation tool is potency assay

Physically unstable



Stabilization Strategy

Water provides mobility, facilitates degradation



- Cryo- Desiccoprotectants
- H-bond donors
- Surfactants
- Glass former
- Antioxidants

- Remove water
- Create morphology
- Determine solid state
 - Mixing
 - Residual water content
 - Glass properties



Processing Options: Spray Drying

Benchtop Scale



Intermediate Scale

Büchi 191

Niro Mobile Minor

Advantages:


- Highly scalable
- Short manufacturing time
- Versatile solid dosage form
- Enables broad delivery options
 - Different delivery routes
 - Different delivery devices

Challenges:

Shear and thermal stress



Spray Drying: Thermal Stress and Stabilization




Foss, W. R., Vehring, R. AAAR Annual Conference, 2004, Atlanta, GA

- During drying, the active is protected from high temperature by evaporative cooling.
- When almost dry, the particle temperature will reach the drying gas temperature but the active is by then immobilized and protected in an amorphous phase.



Processing Options: Foam Freeze Drying and Freeze Drying




Foam Freeze Drying:

- Higher shelf temperatures
- Shorter cycle time




Characteristics of Foam Freeze Drying





Spray Drying Stabilizes Live Virus Vaccine




- Cold-adapted, attenuated influenza B/Harbin virus
- Spray drying conditions
 - 55 65 °C drying gas temperature
 - 32 38 °C collector temperature
 - 1 15 µm particle diameter
 - Solid state properties

- Amorphous, sucrose based
- 55 75 °C glass transition temperature
- 1.5 4 % moisture content

Room temperature stability is feasible !



Process Conditions Affect Initial Loss and Stability



Truong-Le, V. Protein and Peptide Formulation Strategies, 2004, San Francisco, CA

T Gas	35 °C	55 °C	85 °C	100 °C
T Product	23 °C	33 °C	44 °C	53 °C
T _G	38 °C	41 °C	44 °C	47 °C
Moisture	2.0 %	1.6 %	1.2 %	1.0 %



Same Formulation – Different Processes

Freeze Drying




Foam Freeze Drying

	Lyo	Foam	
T _G	53	46	°C
Specific Surface Area	0.9	0.06	m²/g
Moisture Content	2.2	2.0	%
Process Loss	- 0.15	- 0.2	Δ log potency
Stability at 25 °C	- 0.6	- 0.04	$\Delta \log / month$



Foam Freeze Drying Stabilizes Live Virus Vaccine




	Process loss	Potency loss rate	Time to 1 log loss
	Log FFU/ml	Log FFU/month	Years @ 25 ^o C
A/Beijing (H1N1) -0.3	-0.017 <u>+</u> 0.005	4.9 <u>+</u> 1.4
A/Sydney (H3N	2) 0	-0.021 <u>+</u> 0.004	3.9 <u>+</u> 0.8
B/Harbin (B)	0	-0.038 <u>+</u> 0.005	2.2 <u>+</u> 0.3

Room temperature stability is feasible

 Significant differences between virus species and strains




Stability at Elevated Temperatures



Dried virus vaccine tolerates excursions to higher temperatures for several days



Shelf Life at Refrigerated Conditions



Long time storage is feasible.



Conclusions

Virus vaccines can be stabilized in dry form

- Room temperature stability for years is achievable
- Excursions to higher temperatures can be tolerated for weeks
- Refrigerated storage opens option of stockpiling vaccines for decades
- Different processing options exist
 - Spray Drying using mild process conditions
 - Freeze Drying or Foam Freeze Drying
- Stabilization depends on processing conditions
- Unite Formulation and Process Development
- Study mechanisms of stabilization and damage

